Published Works | Inside Litigation | 01 June 2006

DOJ Teaches a Lesson in Healthcare Marketing

In a major enforcement strategy shift, the U.S. Department of Justice (DOJ) has taken firm control of enforcement against pharmaceutical and biotech manufacturers. Both "Main Justice" in Washington and various U.S. Attorney Offices around the country now enforce against pharmaceutical companies through not only the Food, Drug, and Cosmetic Act, but also the Anti-Kickback statute and the False Claims Act.

Download PDF Back To Listing